(19)
(11) EP 2 970 424 A2

(12)

(88) Date of publication A3:
27.11.2014

(43) Date of publication:
20.01.2016 Bulletin 2016/03

(21) Application number: 14722420.8

(22) Date of filing: 12.03.2014
(51) International Patent Classification (IPC): 
C07K 14/575(2006.01)
(86) International application number:
PCT/US2014/024706
(87) International publication number:
WO 2014/165189 (09.10.2014 Gazette 2014/41)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 13.03.2013 US 201361779337 P

(71) Applicants:
  • Eli Lilly and Company
    Indianapolis, IN 46285 (US)
  • Ambrx, Inc.
    La Jolla, CA 92037 (US)

(72) Inventors:
  • BLEDSOE, Michael
    San Diego, California 92122 (US)
  • CANNING, Peter Connor
    Indianapolis, Indiana 46206-6288 (US)
  • DEGUZMAN, Michael
    La Jolla, California 92037 (US)
  • KNUDSEN, Nick
    La Jolla, California 92037 (US)
  • VALENTA, Ianina
    La Jolla, California 92037 (US)

(74) Representative: Bassinder, Emma Marie 
Eli Lilly and Company Limited European Patent Operations Erl Wood Manor Sunninghill Road
Windlesham, Surrey GU20 6PH
Windlesham, Surrey GU20 6PH (GB)

   


(54) MODIFIED CANINE LEPTIN POLYPEPTIDES